Additionally, on December 20, Oliviero transferred 900,000 shares to an irrevocable trust for his minor children. This transfer was effected at no cost, and Oliviero has no control over the investment in securities held by the Trust. Following these transactions, Oliviero retains ownership of 2,294,583 shares Checkpoint treatments (Nasdaq:). InvestingPro Subscribers can access additional insights, including 8 key investment tips and detailed metrics for CKPT's financial health. InvestingPro Subscribers can access additional insights, including 8 key investment tips and detailed metrics for CKPT's financial health.
Additionally, on December 20, Oliviero transferred 900,000 shares to an irrevocable trust for his minor children. This transfer was effected at no cost, and Oliviero has no control over the investment in securities held by the Trust. Following these transactions, Oliviero retains ownership of 2,294,583 shares of Checkpoint Therapeutics.
In other recent news, Checkpoint Therapeutics has been the focus of several important developments. EPS for the second quarter beat consensus estimates of $0.18. In addition, the company received an additional $12 million from a recent offering.
Checkpoint Therapeutics also reported promising results from its cosibelimab trial, where objective response rates exceeded previous observations. The company has set a Prescription Drug User Fee Act target date of December 28, 2024 for its biosimilar license application for cosibelimab.
Lake Street Capital Markets upgraded its price target on Checkpoint Therapeutics from $4 to $7 while maintaining a Buy rating. The company expressed confidence in the company's continued growth through 2025. Meanwhile, HC Wainwright reiterated a Buy rating on the stock, highlighting the potential market opportunity for cosibelimab.
In other company news, Checkpoint Therapeutics announced a stock sale expected to generate approximately $12 million and a partnership with GC Cell to evaluate its cancer therapeutics portfolio. These are among the latest developments in Checkpoint Therapeutics' ongoing efforts in immunotherapy and targeted oncology.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
